Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the American College of Cardiology (ACC) Annual Meeting, which convenes from March 29-31 in Chicago, Illinois. This is the first year that Tempus is presenting research, all of which highlights the application of AI to support clinicians in delivering personalized care.

“Tempus is committed to enabling clinicians to provide better, guideline-recommended care to patients who may have undiagnosed or undertreated cardiovascular disease,” said Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiology at Tempus. “Through our vast connected network of providers and ability to deliver AI-enabled insights at scale, we can help clinicians close care gaps for patients in a way that wasn’t possible before.”

Highlights from Tempus’ abstracts include:

• Abstract 184: Development of machine learning models incorporating clinical, demographic, and echocardiography variables for predicting left ventricular systolic dysfunction in patients with isolated left ventricular dilation
  • Session Date & Time: Saturday, March 29, 9:30 AM CDT
  • Overview: The goal of this study is to create predictive models for the development of left ventricular (LV) systolic dysfunction in patients with isolated LV dilation (ILVD). This preliminary work identifies predictors and demonstrates the ability to predict progression in patients with ILVD.
• Abstract 140: Implementation of EHR-integrated notifications on patients at risk for sudden cardiac arrest
  • Session Date & Time: Saturday, March 29, 11:00 AM CDT
  • Overview: This study looks at the implementation of electronic health record (EHR) integrated notifications to identify patients at risk for sudden cardiac arrest (SCA) who may benefit from Implantable Cardioverter Defibrillators (ICD). The conclusion is EHR-integrated notifications can help close care gaps for undermanaged patients at risk for SCA.
• Abstract 127: Addressing racial disparities in valvular heart disease: the role of echo-driven EHR alerts in improving care access
  • Session Date & Time: Saturday, March 29, 11:00 AM CDT
  • Overview: The focus of this study is on addressing racial disparities in valvular heart disease, specifically severe aortic stenosis (SAS) and severe mitral regurgitation (SMR). The study observed race-based trends in access to appropriate care for patients at a tertiary care center from April 2019 to January 2024.
• Abstract 174: Enhancing diagnostic accuracy and treatment appropriateness in cardiac transthyretin amyloidosis through natural language processing: a retrospective analysis
  • Session Date & Time: Sunday, March 30, 9:00 AM CDT
  • Overview: This study looked at the challenges of diagnosing cardiac transthyretin amyloidosis (cardiac ATTR) and how natural language processing (NLP) can help. The study concludes that significant care gaps exist in managing cardiac ATTR and that integrating NLP into clinical workflows can improve diagnostic accuracy and help patients access therapies.

To learn more, visit www.tempus.co/acc-2025.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of these abstracts; the contributions of these abstracts to the larger scientific community, and the use of Tempus’ products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; including our ability to realize the expected benefits of the acquisition of Ambry Genetics; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Contacts

Hanah Heintzelman

media@tempus.com